Vicore sells rights to IPF drug in Japan; Roche to lay off 340 workers; Sensorion’s €50M offering

09 Feb 2024
endpts.com
License out/in
Nippon Shinyaku gets rights in Japan to IPF drug: The Japanese pharma company is paying Vicore Pharma $10 million upfront in a deal worth up to $275 million for Japan rights to C21, an angiotensin II type 2 receptor agonistangiotensin II type 2 receptor agonist. Nippon Shinyaku is licensing the oral drug candidate for idiopathic pulmonary fibrosis, a chronic condition where the lungs become scarred and it’s hard for patients to breathe. — Lei Lei Wu
Vicore sells rights to IPF drug in Japan; Roche to lay off 340 workers; Sensorion’s €50M offering
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.